CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
EP2214691B1
(en)
|
2007-10-30 |
2015-09-30 |
Indiana University Research and Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
EP2217701B9
(en)
|
2007-10-30 |
2015-02-18 |
Indiana University Research and Technology Corporation |
Glucagon antagonists
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
US8906847B2
(en)
*
|
2008-02-01 |
2014-12-09 |
Ascendis Pharma A/S |
Prodrug comprising a drug linker conjugate
|
SI3050576T1
(sl)
|
2008-04-29 |
2021-08-31 |
Ascendis Pharma Endocrinology Division A/S |
Spojine pegiliranega rekombinantnega humanega rastnega hormona
|
TWI474832B
(zh)
|
2008-06-17 |
2015-03-01 |
Univ Indiana Res & Tech Corp |
胰高血糖素/glp-1受體共同激動劑
|
CN102088989B
(zh)
|
2008-06-17 |
2014-11-26 |
印第安纳大学研究及科技有限公司 |
在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
|
CA2729296A1
(en)
|
2008-06-17 |
2010-01-28 |
Richard D. Dimarchi |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
WO2010042596A2
(en)
*
|
2008-10-08 |
2010-04-15 |
The Uab Research Foundation |
Photo-activated protecting groups
|
AU2009335712B2
(en)
|
2008-12-19 |
2015-09-17 |
Indiana University Research And Technology Corporation |
Insulin analogs
|
BRPI0922969A2
(pt)
|
2008-12-19 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
pró-farmaco de amida baseado na superfamília de glucagon peptídeo.
|
CA2744558A1
(en)
|
2008-12-19 |
2010-07-15 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
US9192681B2
(en)
|
2009-02-24 |
2015-11-24 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
KR102033680B1
(ko)
|
2009-05-20 |
2019-10-18 |
바이오마린 파머수티컬 인크. |
씨형 나트륨이뇨 펩티드의 변이체
|
BRPI1014508A2
(pt)
|
2009-06-16 |
2016-04-05 |
Univ Indiana Res & Tech Corp |
análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
|
JP5738291B2
(ja)
|
2009-07-31 |
2015-06-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリンリンカー複合体を含むプロドラッグ
|
DK2459171T3
(en)
|
2009-07-31 |
2017-09-25 |
Sanofi Aventis Deutschland |
Long-acting insulin composition
|
MX343925B
(es)
|
2009-07-31 |
2016-11-29 |
Ascendis Pharma As |
Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.
|
WO2011012722A1
(en)
*
|
2009-07-31 |
2011-02-03 |
Ascendis Pharma As |
Prodrugs containing an aromatic amine connected by an amido bond to a linker
|
WO2011042453A1
(en)
|
2009-10-06 |
2011-04-14 |
Ascendis Pharma As |
Subcutaneous paliperidone composition
|
CN102686245B
(zh)
|
2009-10-29 |
2015-09-30 |
阿森迪斯药物股份有限公司 |
可生物降解水凝胶的消毒
|
MX337432B
(es)
*
|
2009-12-15 |
2016-03-04 |
Ascendis Pharma As |
Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
WO2011089215A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
US9561285B2
(en)
|
2010-01-22 |
2017-02-07 |
Ascendis Pharma As |
Carrier-linked carbamate prodrug linkers
|
US9062094B2
(en)
|
2010-01-22 |
2015-06-23 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
BR112012018585A2
(pt)
|
2010-01-27 |
2017-01-10 |
Univ Indiana Res & Tech Corp |
conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
|
US20120035320A1
(en)
*
|
2010-04-03 |
2012-02-09 |
University Of Iowa Research Foundation |
Polyacridine nucleic acid delivery peptide complexes
|
BR112012028707A2
(pt)
|
2010-05-13 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
|
US9127088B2
(en)
|
2010-05-13 |
2015-09-08 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
CN103068842B
(zh)
|
2010-06-16 |
2016-10-19 |
印第安纳大学研究及科技有限公司 |
对胰岛素受体具有高活性的单链胰岛素激动剂
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
WO2011163462A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
EP2438930A1
(en)
*
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
MX2013006304A
(es)
|
2010-12-22 |
2013-07-02 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad del receptor gip.
|
WO2012177444A2
(en)
|
2011-06-22 |
2012-12-27 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
EA032840B8
(ru)
|
2011-06-22 |
2020-06-18 |
Вайоми Терапеутикс Лимитед |
Пролекарства на основе конъюгатов противогрибковых агентов и их применение
|
AU2012286048A1
(en)
|
2011-07-18 |
2014-02-20 |
Arts Biologics A/S |
Long acting luteinizing hormone (LH) compound
|
CA2843504C
(en)
*
|
2011-08-12 |
2020-08-25 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
WO2013024047A1
(en)
|
2011-08-12 |
2013-02-21 |
Ascendis Pharma A/S |
High-loading water-soluble carrier-linked prodrugs
|
CA2843503C
(en)
|
2011-08-12 |
2020-12-22 |
Ulrich Hersel |
Polymeric hyperbranched carrier-linked prodrugs
|
EP2741744A1
(en)
|
2011-08-12 |
2014-06-18 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
MY171920A
(en)
|
2011-10-12 |
2019-11-07 |
Ascendis Pharma Ophthalmology Div A/S |
Prevention and treatment of ocular conditions
|
WO2013059323A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Prolynx Llc |
Peg conjugates of exenatide
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
EP2793932B1
(en)
|
2011-12-20 |
2018-10-03 |
Indiana University Research and Technology Corporation |
Ctp-based insulin analogs for treatment of diabetes
|
AU2013254756B2
(en)
*
|
2012-04-25 |
2017-03-30 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
WO2013167750A2
(en)
|
2012-05-11 |
2013-11-14 |
Prorec Bio Ab |
Method for diagnosis and treatment of prolactin associated disorders
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
WO2014036395A1
(en)
*
|
2012-08-30 |
2014-03-06 |
The Scripps Research Institute |
SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES
|
EP2900255B1
(en)
|
2012-09-26 |
2019-01-30 |
Indiana University Research and Technology Corporation |
Insulin analog dimers
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
MX2015003792A
(es)
|
2012-10-11 |
2015-07-14 |
Ascendis Pharma As |
Profarmacos de hidrogel.
|
AU2013328782C1
(en)
|
2012-10-11 |
2018-01-18 |
Ascendis Pharma Ophthalmology Division A/S |
VEGF neutralizing prodrugs for the treatment of ocular conditions
|
JP6355636B2
(ja)
|
2012-10-11 |
2018-07-11 |
アセンディス ファーマ エー/エス |
関節の疾患の診断、予防及び治療
|
WO2014080730A1
(ja)
*
|
2012-11-22 |
2014-05-30 |
株式会社糖鎖工学研究所 |
糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法
|
EP2926829B1
(en)
|
2012-11-30 |
2018-07-25 |
Glytech, Inc. |
Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
|
AR094181A1
(es)
|
2012-12-21 |
2015-07-15 |
Sanofi Sa |
Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
|
CA2904332A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
WO2014173759A1
(en)
|
2013-04-22 |
2014-10-30 |
Ascendis Pharma A/S |
Hydrogel-linked prodrugs releasing modified drugs
|
CN104177465B
(zh)
*
|
2013-05-21 |
2017-09-29 |
成都先导药物开发有限公司 |
一种化合物给药前体及药物载体制剂
|
JP6276390B2
(ja)
*
|
2013-05-21 |
2018-02-07 |
成都先導薬物開発有限公司 |
化合物の細胞膜透過の方法
|
AU2014333953C1
(en)
*
|
2013-10-08 |
2020-06-25 |
Ascendis Pharma A/S |
Hydrogel-linked IL-1ra prodrug
|
EP3054981B1
(en)
*
|
2013-10-08 |
2020-07-29 |
Ascendis Pharma A/S |
Protecting group comprising a purification tag
|
WO2015067791A1
(en)
|
2013-11-11 |
2015-05-14 |
Ascendis Pharma Relaxin Division A/S |
Relaxin prodrugs
|
CA2932477C
(en)
|
2013-12-06 |
2023-10-10 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
KR101768446B1
(ko)
|
2014-03-21 |
2017-08-17 |
애니젠 주식회사 |
신규한 엑세나타이드 유사체 및 그의 용도
|
CN104945499B
(zh)
*
|
2014-03-31 |
2019-12-10 |
博瑞生物医药(苏州)股份有限公司 |
结构修饰的glp-1类似物及其制备方法
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
ES2779974T3
(es)
|
2014-06-13 |
2020-08-21 |
Tenboron Oy |
Conjugados que comprenden un anticuerpo anti-egfr1
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
AU2015299055C1
(en)
|
2014-08-06 |
2021-05-06 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
WO2016049190A1
(en)
|
2014-09-24 |
2016-03-31 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
CN107001441A
(zh)
|
2014-09-24 |
2017-08-01 |
印第安纳大学研究及科技有限公司 |
脂质化的基于酰胺的胰岛素前药
|
JP6946182B2
(ja)
|
2014-10-22 |
2021-10-06 |
エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc |
治療用ビタミンdコンジュゲート
|
US10265413B2
(en)
|
2014-11-05 |
2019-04-23 |
University Of The Sciences In Philadelphia |
High molecular weight biodegradable gelatin-doxorubicin conjugate
|
SG11201705521YA
(en)
*
|
2015-01-09 |
2017-08-30 |
Ascendis Pharma Growth Disorders As |
Cnp prodrugs
|
WO2016196124A2
(en)
|
2015-05-29 |
2016-12-08 |
Ascendis Pharma Inc. |
Prodrugs comprising a pyroglutamate linker
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
MY191756A
(en)
|
2015-09-23 |
2022-07-14 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药(苏州)股份有限公司 |
艾塞那肽修饰物及其用途
|
CN107043406B
(zh)
|
2015-11-03 |
2021-08-17 |
财团法人工业技术研究院 |
化合物、连接子-药物、及配体-药物耦合体
|
PL3400019T3
(pl)
*
|
2016-01-08 |
2023-01-23 |
Ascendis Pharma Growth Disorders A/S |
Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
|
AU2017205273C1
(en)
|
2016-01-08 |
2022-12-01 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with reduced side-effects
|
IL259829B2
(en)
*
|
2016-01-08 |
2023-03-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low npr–c binding
|
US11224661B2
(en)
|
2016-01-08 |
2022-01-18 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with increased NEP stability
|
MX2018008061A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
|
AU2017205693B2
(en)
*
|
2016-01-08 |
2022-03-31 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low initial NPR-B activity
|
WO2017127528A1
(en)
*
|
2016-01-19 |
2017-07-27 |
University Of Florida Research Foundation, Inc. |
Peptoid agonists of fibroblast growth receptors
|
SG11201806092TA
(en)
*
|
2016-03-01 |
2018-08-30 |
Ascendis Pharma Bone Diseases As |
Pth prodrugs
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
BR112018071972A2
(pt)
|
2016-04-29 |
2019-02-26 |
Defensin Therapeutics Aps |
métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
|
CA3030376A1
(en)
|
2016-07-13 |
2018-01-18 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
HRP20230385T1
(hr)
|
2016-09-29 |
2023-06-23 |
Ascendis Pharma Growth Disorders A/S |
Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem
|
CN109789221B
(zh)
*
|
2016-09-29 |
2022-11-01 |
阿森迪斯药物骨疾病股份有限公司 |
控释pth的药物组合物
|
DK3518960T3
(da)
|
2016-09-29 |
2023-09-04 |
Ascendis Pharma Bone Diseases As |
Doseringsskema for en PTH-forbindelse med kontrolleret frigivelse
|
HUE062009T2
(hu)
|
2016-09-29 |
2023-09-28 |
Ascendis Pharma Bone Diseases As |
Alacsony peak to trough arányú PTH vegyületek
|
TW201832783A
(zh)
|
2016-12-02 |
2018-09-16 |
法商賽諾菲公司 |
包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物
|
SG10202012106WA
(en)
|
2016-12-13 |
2021-01-28 |
Defensin Therapeutics Aps |
Methods for treating inflammatory conditions of the lungs
|
EP3598866A1
(en)
*
|
2016-12-29 |
2020-01-29 |
Development Center for Biotechnology |
Klk6-mediated cns-specific antibody prodrug activation
|
EP3592393B1
(en)
|
2017-03-10 |
2021-12-01 |
QuiaPEG Pharmaceuticals AB |
Releasable conjugates
|
SG11201908547VA
(en)
|
2017-03-22 |
2019-10-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
AU2018351936A1
(en)
*
|
2017-10-06 |
2020-05-14 |
Fundação Calouste Gulbenkian |
Treatment of obesity-related conditions
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
CN111556759A
(zh)
|
2017-11-10 |
2020-08-18 |
防御素治疗学公司 |
早产儿中的粘膜防御和肠道/肺功能的成熟化
|
EP3713590A2
(en)
|
2017-11-24 |
2020-09-30 |
Defensin Therapeutics ApS |
Prevention and treatment of graft-versus-host-disease with defensins
|
CN109160883B
(zh)
*
|
2017-11-30 |
2021-10-08 |
银隆新能源股份有限公司 |
一种蒽醌盐正极材料及其合成方法
|
KR20200110317A
(ko)
|
2017-12-05 |
2020-09-23 |
선오비온 파마슈티컬스 인코포레이티드 |
결정형 및 이의 제조 방법
|
KR20200110648A
(ko)
|
2017-12-05 |
2020-09-24 |
선오비온 파마슈티컬스 인코포레이티드 |
비라세믹 혼합물 및 이의 용도
|
AU2018378812A1
(en)
|
2017-12-06 |
2020-07-09 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
WO2019185706A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
BR112020019639A2
(pt)
|
2018-03-28 |
2021-01-05 |
Ascendis Pharma Oncology Division A/S |
Conjugados de il-2
|
US10799138B2
(en)
|
2018-04-05 |
2020-10-13 |
University Of Maryland, Baltimore |
Method of administering sotalol IV/switch
|
US11560402B2
(en)
|
2018-04-10 |
2023-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Method for cleavage of solid phase-bound peptides from the solid phase
|
EP3774838B1
(en)
|
2018-04-10 |
2022-08-10 |
Sanofi-Aventis Deutschland GmbH |
Lixisenatide synthesis with capping
|
US20210196801A1
(en)
*
|
2018-05-18 |
2021-07-01 |
Ascendis Pharma Bone Diseases A/S |
Starting Dose of PTH Conjugates
|
TW202015735A
(zh)
|
2018-05-30 |
2020-05-01 |
法商賽諾菲公司 |
包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物
|
US11696902B2
(en)
|
2018-08-14 |
2023-07-11 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
US11344518B2
(en)
|
2018-08-14 |
2022-05-31 |
AltaThera Pharmaceuticals LLC |
Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
|
US11610660B1
(en)
|
2021-08-20 |
2023-03-21 |
AltaThera Pharmaceuticals LLC |
Antiarrhythmic drug dosing methods, medical devices, and systems
|
US10512620B1
(en)
|
2018-08-14 |
2019-12-24 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
US11357828B2
(en)
|
2018-09-12 |
2022-06-14 |
Quiapeg Pharmaceuticals Ab |
Releasable GLP-1 conjugates
|
EP3856256A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
AU2019350376A1
(en)
|
2018-09-26 |
2021-03-18 |
Ascendis Pharma A/S |
Treatment of infections
|
EP3856257A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣3多肽之持續遞送
|
CN109125707B
(zh)
*
|
2018-10-19 |
2022-01-04 |
艾伟伦 |
GnRH类似物缓释组合物及其制备方法
|
EP3906032A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Sustained local drug levels for innate immune agonists
|
SG11202105835YA
(en)
|
2019-01-04 |
2021-07-29 |
Ascendis Pharma Oncology Div A/S |
Conjugates of pattern recognition receptor agonists
|
WO2020141225A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Minimization of systemic inflammation
|
WO2020141223A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Induction of sustained local inflammation
|
SG11202107446QA
(en)
|
2019-02-11 |
2021-08-30 |
Ascendis Pharma Growth Disorders As |
Dry pharmaceutical formulations of cnp conjugates
|
WO2020165087A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of pth conjugates
|
KR20220008824A
(ko)
|
2019-04-17 |
2022-01-21 |
컴퍼스 패쓰파인더 리미티드 |
실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
|
BR112021024380A2
(pt)
|
2019-06-04 |
2022-04-19 |
Sunovion Pharmaceuticals Inc |
Formulações de liberação modificadas e usos das mesmas
|
US20230102309A1
(en)
|
2019-06-21 |
2023-03-30 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
AU2020295725A1
(en)
|
2019-06-21 |
2021-12-02 |
Ascendis Pharma Oncology Division A/S |
Anti-CTLA4 conjugates
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
EP3986472A1
(en)
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
CN114026080A
(zh)
|
2019-06-21 |
2022-02-08 |
阿森迪斯药物股份有限公司 |
含有提供π-电子对的杂芳族氮的化合物的缀合物
|
JP2023512427A
(ja)
|
2020-01-03 |
2023-03-27 |
アセンディス ファーマ エー/エス |
分子内転位を受けるコンジュゲート
|
BR112022010419A2
(pt)
|
2020-01-13 |
2022-08-23 |
Ascendis Pharma Bone Diseases As |
Tratamento de hipoparatireoidismo
|
EP4121063A1
(en)
|
2020-03-19 |
2023-01-25 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
US20230241217A1
(en)
|
2020-05-04 |
2023-08-03 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
CN116133676A
(zh)
|
2020-06-03 |
2023-05-16 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2序列及其用途
|
AU2021319863A1
(en)
|
2020-08-05 |
2023-02-16 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
EP4204439A1
(en)
|
2020-08-28 |
2023-07-05 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
EP4211130A1
(en)
*
|
2020-09-11 |
2023-07-19 |
COMPASS Pathfinder Limited |
Novel safrylamine derivatives having prodrug properties
|
CA3192772A1
(en)
|
2020-09-28 |
2022-03-31 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
AU2022246997A1
(en)
|
2021-04-01 |
2023-09-28 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
CN113842379B
(zh)
*
|
2021-09-12 |
2024-04-23 |
东北农业大学 |
倍他洛尔作为ndm-1抑制剂或抗生素保护剂的新用途
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
WO2023046732A1
(en)
|
2021-09-22 |
2023-03-30 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
WO2023056102A1
(en)
|
2021-10-01 |
2023-04-06 |
ATAI Life Sciences AG |
Novel prodrugs of mdma, mda, and derivatives thereof
|
WO2023110727A2
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with tlr7/8 agonists
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
US11912680B2
(en)
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|